Best of 2022: EULAR 2022 Top 10 Abstracts Save
Editor's note: this article originally appeared June 10, 2022, and is being shared again as a Best of 2022. Enjoy!
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media…
Depression and RA DANBIO OP0067: Depression is a major risk factor (6X!) for mortality in RA.
EULAR 2022 Updated recommendations for the management of rheumatoid arthritis
Steroids in RA – the GLORIA GLORIA promotes Steroids! Abstract #OP0263
Oral Surveillance (1133) Rehashed
Buch MH, et al. POS0237
Charles-Schoeman C, et al.
Karpouzas G, et al. POS0519
Giles JT, et al. POS0520
CAR-T Cell Therapy in SLE. Abstract OP0279
ARIAA – Abatacept in Pre-Clinical RA Has persistent effects! Abstract #POS0531.
EARLIER study OP0070
PMR and Sarilumab SAPHYR Study: Abstract LB0006
Anti-malarials in combination with bDMARDs and tsDMARDs Abstract #POS0242
Topical Bicarbonate for Gouty Attacks? Abstract OP0179
Honorable Mention:
Serious infections causing serious flares of SLE Infections Drive SLE Flares. Abstract OP0143
TYK2 inhibition in SLE Deucravacitinib Succeeds in SLE Phase 2 study. Abstract LB0004 “PAISLEY” study
BE OPTIMAL – Bimekizumab in bDMARD-naïve PsA. Abstract LB0001
Bimekizumab BE COMPLETE trial. Abstract OP0255
ADD THE FIRST COMMENT
Disclosures
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.